Karnataka flags 52-fold markups on cancer drugs, seeks central pricing rules

The Karnataka government has approached the Union Ministry of Health and Family Welfare seeking urgent regulatory intervention after state inspections uncovered price markups of up to 52 times on high-cost cancer medications and medical consumables. Special verification drives conducted across Bengaluru and multiple districts exposed severe financial disparities between the actual procurement costs paid by hospitals and the maximum retail prices billed to vulnerable patients.

The findings highlight deep structural vulnerabilities within India's healthcare pricing framework, where institutional discounts negotiated by large facilities are rarely passed down to in-patients. As out-of-pocket medical expenses continue to push families toward financial distress, the state's disclosures have turned national attention toward the unregulated trade margins applied by private hospital pharmacies on critical therapies.

According to data released by the Karnataka Food Safety and Drug Administration, pharmaceutical companies supply specialised medicines to medical institutions at heavily discounted landing prices, while patients are billed near or at the printed maximum retail price. In a letter sent to the Union Health Ministry on September 23, the state administration detailed 253 drugs carrying extreme pricing anomalies.

Specific instances cited in the state's dossier reveal startling markups. An antibiotic named Gufipol, possessing an institutional landing cost of ₹80, was billed to a patient at ₹4,528, marking a 5,165 per cent increase. Similarly, Guficycline-50 injections procured at ₹160 were charged at ₹7,110, while anti-cancer formulations such as Taxocare 120 mg, purchased at ₹1,000, carried a retail bill of ₹21,617.

Common hospital consumables displayed comparable escalation. An adult nebuliser mask with a landing cost of ₹44.50 was billed to patients at ₹950, and standard intravenous sets procured at ₹14.75 appeared on final bills at ₹295. Under current federal guidelines, scheduled drugs governed by the Drug Price Control Order feature capped retailer margins, whereas non-scheduled formulations and medical devices remain free from strict margin limitations.

To counter these practices, Karnataka has proposed a series of sweeping national reforms. The recommendations include mandatory cost-to-maximum retail price transparency on itemised patient bills, an expansion of the National List of Essential Medicines, and the establishment of an inter-ministerial expert group to rationalise trade margins. State authorities have also called for formal enforcement mechanisms to treat back-end commercial considerations as part of overall acquisition costs.

Drug enforcement teams intend to expand their verification operations in subsequent phases, shifting focus toward anti-retroviral treatments, critical antibiotics, and high-end surgical implants. Whether federal regulators will amend the existing Drugs Prices Control Order to curb institutional markups remains contingent on the Union Ministry's response to the state's formal submissions.